Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Background: PTEN-deficient tumors are dependent on PI3Kβ activity, making PI3Kβ a compelling target. We evaluated the efficacy of PI3Kβ inhibitor AZD8186 on tumors with PTEN loss. Results: In vitro cell viability assay and immunoblotting demonstrated that PTEN loss was significantly correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W., Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082117/
https://www.ncbi.nlm.nih.gov/pubmed/32215185
http://dx.doi.org/10.18632/oncotarget.27503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082117/
https://www.ncbi.nlm.nih.gov/pubmed/32215185
http://dx.doi.org/10.18632/oncotarget.27503

Ejemplares similares